NRx Pharmaceuticals, Inc. (NRXP) Q2 FY26 Earnings Call

$26.7 million cash supports at least one year; 5 million units are ordered ahead of 2026 approval. [2][5]

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-14
Length36 minutes
EPS$-0.18
EPS consensus$-0.09
Revenue$1.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All NRXP earnings ยท Back to NRXP overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.